Comprehensive Report on the Allergy Conjunctivitis Market: Opportunities and Challenges
Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the allergy conjunctivitis industry.
What Is The Expected CAGR For The Allergy Conjunctivitis Market Through 2025?
The allergy conjunctivitis market size has grown steadily in recent years. It will grow from $2.51 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to increasing incidence of allergic conditions, advancements in research and development, changing lifestyles and environmental factors, expansion of patient awareness, collaborations and partnerships, healthcare infrastructure development.
The allergy conjunctivitis market size is expected to see strong growth in the next few years. It will grow to $3.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing global allergy burden, personalized medicine approaches, growing geriatric population, biotechnological innovations, expanding healthcare access in developing regions, regulatory support and approvals. Major trends in the forecast period include integration of novel drug delivery technologies, emphasis on patient education and awareness, development of combination therapies, incorporation of artificial intelligence (ai) in diagnosis, rise in environmental allergen management solutions.
Get your free sample today:
Allergy Conjunctivitis Market Report 2025
Which Key Factors Will Influence Allergy Conjunctivitis Market Growth Over 2025-2034?
The rise in exposure to air pollutants and chemicals is expected to boost the growth of the allergy conjunctivitis market going forward. Human eyes, one of the most sensitive parts of the human body, are constantly at risk due to ongoing exposure to the poisons in air pollution. Long-term exposure to airborne pollutants and chemicals causes a variety of eye issues, including allergic conjunctivitis, allergies, burning, watering, blurred vision, redness, itching, and persistent discomfort, requiring treatments. For instance, in April 2022, according to the World Health Organization, a Switzerland-based international public health organization, nearly the entire global population (99%) is exposed to air that surpasses the World Health Organization's air quality standards, posing a risk to their health. A record-breaking number of over 6,000 cities across 117 countries are now monitoring air quality. However, residents in these cities continue to inhale unhealthy levels of fine particulate matter and nitrogen dioxide, with those in low and middle-income countries facing the highest levels of exposure. Therefore, the rise in exposure to air pollutants and chemicals is driving the growth of the allergy conjunctivitis market.
Comprehensive Segment-Wise Insights Into The Allergy Conjunctivitis Market
The allergy conjunctivitis market covered in this report is segmented –
1) By Drug Class: Antihistamines And Mast Cell Stabilizers, Corticosteroids, Other Drug Classes
2) By Disease Type: Mild, Severe
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antihistamines And Mast Cell Stabilizers: Topical Antihistamines, Oral Antihistamines, Mast Cell Stabilizers
2) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
3) By Other Drug Classes: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Combination Therapy, Immunotherapy, Leukotriene Receptor Antagonists
What Are The Prominent Trends In The Allergy Conjunctivitis Market?
Product innovation is the key trend gaining popularity in the allergy conjunctivitis market. Major companies operating in the allergy conjunctivitis market are focused on developing innovative and advanced products to strengthen their market position. For instance, in March 2022, Allergan, an Irish- US-based medical company launched LASTACAFT, an eye allergy drops. The LASTACAFT brand provides relief in as little as three minutes from itchiness and allergies and lasts through 16 hours. LASTACAFT is instilled directly in the eye to block the histamines that initiate ocular itching to quickly calm the allergic response and provide relief throughout the day from itchy eyes. This solution is an antihistamine eye drop that temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair, and dander for ages two and older. With this new solution, the company can provide quality eye care products and expands their retail eye drop portfolio.
Analysis Of Key Players In Allergy Conjunctivitis Market
Major companies operating in the allergy conjunctivitis market are Allergan PLC, AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alcon Inc., Alembic Pharmaceuticals Ltd., Atopix Therapeutics Ltd., Auven Therapeutics Management LLLP, Bausch & Lomb, Cipla Ltd., Grevis Pharmaceutical Private Limited, Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd., Novartis AG, Ocular Therapeutix Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Laboratoires Thea SAS, Aciex Therapeutics Inc., Bausch Health Companies Inc., C.H. Boehringer Sohn AG & Co. KG, Eyevance Pharmaceuticals LLC, Johnson & Johnson Services Inc., Mylan N.V., Nicox S.A., Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Shire PLC, Teva Pharmaceutical Industries Ltd., Zydus Cadila
View the full allergy conjunctivitis market report here:
Allergy Conjunctivitis Market Report 2025
What Are The Key Regional Trends In The Allergy Conjunctivitis Market?
North America was the largest region in the allergy conjunctivitis market share in 2024. The regions covered in the allergy conjunctivitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Contact Us:#
The Business Research Company
Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
#Follow Us On:#
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment